F8 and hemophilia A: Recently, the innovative FVIII mimetic, emicizumab, was developed with the aim of addressing the unmet needs in hemophilia A. Emicizumab was approved for use in the United States in 2017 [7], Europe and Japan in 2018 [8,9], and subsequently by many other countries.